Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals REGN revealed 11 unusual trades.
Delving into the details, we found 36% of traders were bullish, while 63% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $420,400, and 6 were calls, valued at $749,603.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $800.0 to $1120.0 for Regeneron Pharmaceuticals over the last 3 months.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Regeneron Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Regeneron Pharmaceuticals's significant trades, within a strike price range of $800.0 to $1120.0, over the past month.
Regeneron Pharmaceuticals 30-Day Option Volume & Interest Snapshot
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| REGN | CALL | SWEEP | BEARISH | 06/20/25 | $1060.00 | $481.5K | 0 | 1 |
| REGN | PUT | TRADE | BEARISH | 01/17/25 | $860.00 | $214.5K | 65 | 53 |
| REGN | PUT | TRADE | BULLISH | 01/17/25 | $950.00 | $75.2K | 66 | 10 |
| REGN | CALL | TRADE | BEARISH | 01/16/26 | $1120.00 | $71.7K | 339 | 7 |
| REGN | CALL | TRADE | BEARISH | 06/20/25 | $970.00 | $68.6K | 5 | 5 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Current Position of Regeneron Pharmaceuticals
- With a volume of 130,176, the price of REGN is down 0.0% at $955.76.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 3 days.
Expert Opinions on Regeneron Pharmaceuticals
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $1005.5.
- Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $1076.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $850.
- An analyst from Barclays persists with their Overweight rating on Regeneron Pharmaceuticals, maintaining a target price of $1020.
- An analyst from RBC Capital has elevated its stance to Outperform, setting a new price target at $1076.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
